Epidermal growth factor receptor (EGFR) signaling pathway was recently identified as an important potential NSCLC therapeutic target.6 Tyrosine kinase inhibitors (TKIs), which regulate the EGFR, are very efficient for the treatment of EGFR-mutated lung cancer and show improved therapeutic efficacy. This evidence concerns the gene EGFR and lung carcinoma.